{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T09:58:41Z","timestamp":1783418321999,"version":"3.54.6"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T00:00:00Z","timestamp":1773187200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T00:00:00Z","timestamp":1773187200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000402","name":"Kay Kendall Leukaemia Fund","doi-asserted-by":"publisher","award":["873"],"award-info":[{"award-number":["873"]}],"id":[{"id":"10.13039\/501100000402","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["C42023\/A29370"],"award-info":[{"award-number":["C42023\/A29370"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["C17199\/A29202"],"award-info":[{"award-number":["C17199\/A29202"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"Department of Health | National Health and Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    High genomic complexity (HGC) is linked to poor prognosis in CLL, but its independent prognostic value remains uncertain amid emerging biomarkers. We analysed copy number alterations (CNA) in 495 untreated patients from (immuno)chemotherapy trials (CLL4, ADMIRE, ARCTIC), incorporating IGHV status, telomere length (TL), targeted sequencing and DNA-methylation subtypes. Patients harboured low (LGC, \u22642 CNAs;\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u2009334), intermediate (IGC, 3\u20134 CNAs;\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200997), or high (HGC, \u22655 CNAs;\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200964) genomic complexity. HGC associated with U-CLL (81%,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.001),\n                    <jats:italic>TP53<\/jats:italic>\n                    -aberration (36%,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.001), short TL (TL-S; 61%,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.05), del13q (50%,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.001) and del11q (22%,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.05). IGC was enriched for\u00a0biallelic\n                    <jats:italic>ATM<\/jats:italic>\n                    disruption and\n                    <jats:italic>BIRC3<\/jats:italic>\n                    deletions (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.001). Trisomy 12 and\n                    <jats:italic>NOTCH1<\/jats:italic>\n                    mutations were enriched in LGC (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.001). HGC associated with shorter progression-free and overall survival in univariate models but only remained independent for OS in CLL4 (HR\u2009=\u20091.61,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.02). Independent prognostic factors included\n                    <jats:italic>TP53<\/jats:italic>\n                    aberration, U-CLL, TL-S and n-CLL. Of 64 HGC patients, 23 had\n                    <jats:italic>TP53<\/jats:italic>\n                    -aberration; 92% of\n                    <jats:italic>TP53<\/jats:italic>\n                    wild-type cases had other high-risk features (TL-S, U-CLL, or n-CLL). HGC may reflect a convergence of high-risk features rather than represent an independent biomarker. The interplay of telomere attrition, IGHV status and DNA methylation subtype necessitates further validation in targeted therapy cohorts to enhance risk assessment in prognostic models.\n                  <\/jats:p>","DOI":"10.1038\/s41375-026-02906-5","type":"journal-article","created":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T06:46:14Z","timestamp":1773211574000},"page":"816-826","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["High-risk molecular features may eclipse genomic complexity in predicting chronic lymphocytic leukemia outcomes; UK clinical trial insights"],"prefix":"10.1038","volume":"40","author":[{"given":"H.","family":"Parker","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Carr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6448-8696","authenticated-orcid":false,"given":"K.","family":"Norris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Nilsson-Takeuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Stevens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Amarasinghe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Kadalayil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8578-4796","authenticated-orcid":false,"given":"M.","family":"Else","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Clifford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Pettitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Munir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3938-8490","authenticated-orcid":false,"given":"A.","family":"Schuh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Walewska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8408-5467","authenticated-orcid":false,"given":"D. M.","family":"Baird","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. G.","family":"Oscier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Pepper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3163-608X","authenticated-orcid":false,"given":"D.","family":"Bryant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0973-8285","authenticated-orcid":false,"given":"J.","family":"Gibson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0972-2881","authenticated-orcid":false,"given":"JC","family":"Strefford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,11]]},"reference":[{"key":"2906_CR1","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1002\/ijc.30222","volume":"139","author":"G Lazarian","year":"2016","unstructured":"Lazarian G, Tausch E, Eclache V, Sebaa A, Bianchi V, Letestu R, et al. TP53 mutations are early events in chronic lymphocytic leukemia disease progression and precede evolution to complex karyotypes. Int J Cancer. 2016;139:1759\u201363.","journal-title":"Int J Cancer"},{"key":"2906_CR2","doi-asserted-by":"publisher","first-page":"e299","DOI":"10.3324\/haematol.2015.140202","volume":"101","author":"P Baliakas","year":"2016","unstructured":"Baliakas P, Puiggros A, Xochelli A, Sutton LA, Nguyen-Khac F, Gardiner A, et al. Additional trisomies amongst patients with chronic lymphocytic leukemia carrying trisomy 12: the accompanying chromosome makes a difference. Haematologica. 2016;101:e299\u2013302.","journal-title":"Haematologica"},{"key":"2906_CR3","doi-asserted-by":"publisher","first-page":"2372","DOI":"10.1182\/blood.2020010536","volume":"138","author":"AS Kittai","year":"2021","unstructured":"Kittai AS, Miller C, Goldstein D, Huang Y, Abruzzo LV, Beckwith K, et al. The impact of increasing karyotypic complexity and evolution on survival in patients with CLL treated with ibrutinib. Blood. 2021;138:2372\u201382.","journal-title":"Blood"},{"key":"2906_CR4","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1111\/bjh.15174","volume":"181","author":"GM Rigolin","year":"2018","unstructured":"Rigolin GM, Saccenti E, Guardalben E, Cavallari M, Formigaro L, Zagatti B, et al. In chronic lymphocytic leukaemia with complex karyotype, major structural abnormalities identify a subset of patients with inferior outcome and distinct biological characteristics JO\u2014British Journal of Haematology. Br J Haematol. 2018;181:229\u201333.","journal-title":"Br J Haematol"},{"key":"2906_CR5","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1002\/hon.2349","volume":"35","author":"Y Le Bris","year":"2016","unstructured":"Le Bris Y, Struski S, Gui\u00e8ze R, Rouvellat C, Prade N, Troussard X, et al. Major prognostic value of complex karyotype in addition to TP53 and IGHV mutational status in first-line chronic lymphocytic leukemia. Hematol Oncol. 2016;35:664\u201370.","journal-title":"Hematol Oncol"},{"key":"2906_CR6","doi-asserted-by":"publisher","first-page":"3495","DOI":"10.1182\/blood-2017-03-772285","volume":"129","author":"GM Rigolin","year":"2017","unstructured":"Rigolin GM, Cavallari M, Quaglia FM, Formigaro L, Lista E, Urso A, et al. In CLL, comorbidities and the complex karyotype are associated with an inferior outcome independently of CLL-IPI. Blood. 2017;129:3495\u20138.","journal-title":"Blood"},{"key":"2906_CR7","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1182\/blood-2018-09-873083","volume":"133","author":"P Baliakas","year":"2019","unstructured":"Baliakas P, Jeromin S, Iskas M, Puiggros A, Plevova K, Nguyen-Khac F, et al. Cytogenetic complexity in chronic lymphocytic leukemia: definitions, associations, and clinical impact. Blood. 2019;133:1205\u201316.","journal-title":"Blood"},{"key":"2906_CR8","doi-asserted-by":"publisher","first-page":"868","DOI":"10.3324\/haematol.2021.278304","volume":"107","author":"A Visentin","year":"2022","unstructured":"Visentin A, Bonaldi L, Rigolin GM, Mauro FR, Martines A, Frezzato F, et al. The complex karyotype landscape in chronic lymphocytic leukemia allows the refinement of the risk of Richter syndrome transformation. Haematologica. 2022;107:868\u201376.","journal-title":"Haematologica"},{"key":"2906_CR9","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1056\/NEJMoa2213093","volume":"388","author":"B Eichhorst","year":"2023","unstructured":"Eichhorst B, Niemann Carsten U, Kater Arnon P, F\u00fcrstenau M, von Tresckow J, Zhang C, et al. First-line venetoclax combinations in chronic lymphocytic leukemia. N Engl J Med. 2023;388:1739\u201354.","journal-title":"N Engl J Med"},{"key":"2906_CR10","doi-asserted-by":"publisher","first-page":"34398","DOI":"10.18632\/oncotarget.26146","volume":"9","author":"MCF Cavallari","year":"2018","unstructured":"Cavallari MCF, Bardi A, Volta E, Melandri A, Tammiso E, Saccenti E, et al. Biological significance and prognostic\/predictive impact of complex karyotype in chronic lymphocytic leukemia. Oncotarget. 2018;9:34398\u2013412.","journal-title":"Oncotarget"},{"key":"2906_CR11","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1182\/blood-2016-01-691550","volume":"128","author":"CD Herling","year":"2016","unstructured":"Herling CD, Klaum\u00fcnzer M, Rocha CK, Altm\u00fcller J, Thiele H, Bahlo J, et al. Complex karyotypes and KRAS and POT1 mutations impact outcome in CLL after chlorambucil-based chemotherapy or chemoimmunotherapy. Blood. 2016;128:395\u2013404.","journal-title":"Blood"},{"key":"2906_CR12","doi-asserted-by":"crossref","unstructured":"Al-Sawaf O, Lilienweiss E, Bahlo J, Robrecht S, Fink A-M, Patz M, et al. High efficacy of venetoclax plus obinutuzumab in patients with complex karyotype and chronic lymphocytic leukemia. Blood. 2020;135:866\u201370.","DOI":"10.1182\/blood.2019003451"},{"key":"2906_CR13","doi-asserted-by":"publisher","first-page":"3612","DOI":"10.1002\/cncr.29566","volume":"121","author":"PA Thompson","year":"2015","unstructured":"Thompson PA, O\u2019Brien SM, Wierda WG, Ferrajoli A, Stingo F, Smith SC, et al. Complex karyotype is a stronger predictor than del(17p) for an inferior outcome in relapsed or refractory chronic lymphocytic leukemia patients treated with ibrutinib-based regimens. Cancer. 2015;121:3612\u201321.","journal-title":"Cancer"},{"key":"2906_CR14","doi-asserted-by":"publisher","first-page":"1910","DOI":"10.1182\/blood-2017-10-810044","volume":"131","author":"S O\u2019Brien","year":"2018","unstructured":"O\u2019Brien S, Furman RR, Coutre S, Flinn IW, Burger JA, Blum K, et al. Single-agent ibrutinib in treatment-na\u00efve and relapsed\/refractory chronic lymphocytic leukemia: a 5-year experience. Blood. 2018;131:1910\u20139.","journal-title":"Blood"},{"key":"2906_CR15","doi-asserted-by":"publisher","first-page":"4042","DOI":"10.1200\/JCO.20.00948","volume":"38","author":"AP Kater","year":"2020","unstructured":"Kater AP, Wu JQ, Kipps T, Eichhorst B, Hillmen P, D\u2019Rozario J, et al. Venetoclax plus rituximab in relapsed chronic lymphocytic leukemia: 4-year results and evaluation of impact of genomic complexity and gene mutations from the MURANO phase III study. J Clin Oncol. 2020;38:4042\u201354.","journal-title":"J Clin Oncol"},{"key":"2906_CR16","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1182\/blood.2023019634","volume":"142","author":"M F\u00fcrstenau","year":"2023","unstructured":"F\u00fcrstenau M, Thus YJ, Robrecht S, Mellink CHM, van der Kevie-Kersemaekers AM, Dubois J, et al. High karyotypic complexity is an independent prognostic factor in patients with CLL treated with venetoclax combinations. Blood. 2023;142:446\u201359.","journal-title":"Blood"},{"key":"2906_CR17","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1038\/s41375-019-0533-6","volume":"34","author":"K-A Kreuzer","year":"2020","unstructured":"Kreuzer K-A, Furman RR, Stilgenbauer S, Dubowy RL, Kim Y, Munugalavadla V, et al. The impact of complex karyotype on the overall survival of patients with relapsed chronic lymphocytic leukemia treated with idelalisib plus rituximab. Leukemia. 2020;34:296\u2013300.","journal-title":"Leukemia"},{"key":"2906_CR18","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.1038\/s41375-019-0446-4","volume":"33","author":"BMC Jebaraj","year":"2019","unstructured":"Jebaraj BMC, Tausch E, Landau DA, Bahlo J, Robrecht S, Taylor-Weiner AN, et al. Short telomeres are associated with inferior outcome, genomic complexity, and clonal evolution in chronic lymphocytic leukemia. Leukemia. 2019;33:2183\u201394.","journal-title":"Leukemia"},{"key":"2906_CR19","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.1182\/blood-2010-02-272104","volume":"116","author":"TT Lin","year":"2010","unstructured":"Lin T T, Letsolo BT, Jones RE, Rowson J, Pratt G, Hewamana S, et al. Telomere dysfunction and fusion during the progression of chronic lymphocytic leukemia: evidence for a telomere crisis. Blood. 2010;116:1899\u2013907.","journal-title":"Blood"},{"key":"2906_CR20","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1002\/ajh.23466","volume":"88","author":"L Mansouri","year":"2013","unstructured":"Mansouri L, Grabowski P, Degerman S, Svenson U, Gunnarsson R, Cahill N, et al. Short telomere length is associated with NOTCH1\/SF3B1\/TP53 aberrations and poor outcome in newly diagnosed chronic lymphocytic leukemia patients. Am J Hematol. 2013;88:647\u201351.","journal-title":"Am J Hematol"},{"key":"2906_CR21","doi-asserted-by":"publisher","first-page":"2246","DOI":"10.1182\/blood-2007-05-092759","volume":"111","author":"G Roos","year":"2008","unstructured":"Roos G, Kr\u00f6ber A, Grabowski P, Kienle D, B\u00fchler A, D\u00f6hner H, et al. Short telomeres are associated with genetic complexity, high-risk genomic aberrations, and short survival in chronic lymphocytic leukemia. Blood. 2008;111:2246\u201352.","journal-title":"Blood"},{"key":"2906_CR22","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1016\/S0960-9822(03)00542-6","volume":"13","author":"H Takai","year":"2003","unstructured":"Takai H, Smogorzewska A, de Lange T. DNA damage foci at dysfunctional telomeres. Curr Biol. 2003;13:1549\u201356.","journal-title":"Curr Biol"},{"key":"2906_CR23","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1182\/blood-2009-12-257618","volume":"116","author":"T Brugat","year":"2010","unstructured":"Brugat T, Nguyen-Khac F, Grelier A, Merle-B\u00e9ral H, Delic J. Telomere dysfunction-induced foci arise with the onset of telomeric deletions and complex chromosomal aberrations in resistant chronic lymphocytic leukemia cells. Blood. 2010;116:239\u201349.","journal-title":"Blood"},{"key":"2906_CR24","doi-asserted-by":"publisher","first-page":"2411","DOI":"10.1038\/leu.2015.217","volume":"29","author":"JC Strefford","year":"2015","unstructured":"Strefford JC, Kadalayil L, Forster J, Rose-Zerilli MJ, Parker A, Lin T T, et al. Telomere length predicts progression and overall survival in chronic lymphocytic leukemia: data from the UK LRF CLL4 trial. Leukemia. 2015;29:2411\u20134.","journal-title":"Leukemia"},{"key":"2906_CR25","doi-asserted-by":"publisher","first-page":"56","DOI":"10.3324\/haematol.2011.049874","volume":"97","author":"E Rampazzo","year":"2012","unstructured":"Rampazzo E, Bonaldi L, Trentin L, Visco C, Keppel S, Giunco S, et al. Telomere length and telomerase levels delineate subgroups of B-cell chronic lymphocytic leukemia with different biological characteristics and clinical outcomes. Haematologica. 2012;97:56\u201363.","journal-title":"Haematologica"},{"key":"2906_CR26","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.1038\/s41375-019-0389-9","volume":"33","author":"K Norris","year":"2019","unstructured":"Norris K, Hillmen P, Rawstron A, Hills R, Baird DM, Fegan CD, et al. Telomere length predicts for outcome to FCR chemotherapy in CLL. Leukemia. 2019;33:1953\u201363.","journal-title":"Leukemia"},{"key":"2906_CR27","first-page":"4918","volume":"58","author":"OE Bechter","year":"1998","unstructured":"Bechter OE, Eisterer W, Pall G, Hilbe W, K\u00fchr T, Thaler J. Telomere length and telomerase activity predict survival in patients with B cell chronic lymphocytic leukemia. Cancer Res. 1998;58:4918\u201322.","journal-title":"Cancer Res"},{"key":"2906_CR28","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1182\/blood-2003-04-1345","volume":"103","author":"RN Damle","year":"2004","unstructured":"Damle RN, Batliwalla FM, Ghiotto F, Valetto A, Albesiano E, Sison C, et al. Telomere length and telomerase activity delineate distinctive replicative features of the B-CLL subgroups defined by immunoglobulin V gene mutations. Blood. 2004;103:375\u201382.","journal-title":"Blood"},{"key":"2906_CR29","doi-asserted-by":"publisher","first-page":"10827","DOI":"10.1073\/pnas.94.20.10827","volume":"94","author":"NP Weng","year":"1997","unstructured":"Weng NP, Granger L, Hodes RJ. Telomere lengthening and telomerase activation during human B cell differentiation. Proc Natl Acad Sci USA. 1997;94:10827\u201332.","journal-title":"Proc Natl Acad Sci USA"},{"key":"2906_CR30","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.4049\/jimmunol.159.3.1068","volume":"159","author":"BT Hu","year":"1997","unstructured":"Hu BT, Lee SC, Marin E, Ryan DH, Insel RA. Telomerase is up-regulated in human germinal center B cells in vivo and can be re-expressed in memory B cells activated in vitro. J Immunol. 1997;159:1068\u201371.","journal-title":"J Immunol"},{"key":"2906_CR31","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1038\/leu.2008.260","volume":"23","author":"OG Best","year":"2009","unstructured":"Best OG, Gardiner AC, Davis ZA, Tracy I, Ibbotson RE, Majid A, et al. A subset of Binet stage A CLL patients with TP53 abnormalities and mutated IGHV genes have stable disease. Leukemia. 2009;23:212\u20134.","journal-title":"Leukemia"},{"key":"2906_CR32","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1038\/ng.2443","volume":"44","author":"M Kulis","year":"2012","unstructured":"Kulis M, Heath S, Bibikova M, Queir\u00f3s AC, Navarro A, Clot G, et al. Epigenomic analysis detects widespread gene-body DNA hypomethylation in chronic lymphocytic leukemia. Nat Genet. 2012;44:1236\u201342.","journal-title":"Nat Genet"},{"key":"2906_CR33","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1038\/ng.3488","volume":"48","author":"CC Oakes","year":"2016","unstructured":"Oakes CC, Seifert M, Assenov Y, Gu L, Przekopowitz M, Ruppert AS, et al. DNA methylation dynamics during B cell maturation underlie a continuum of disease phenotypes in chronic lymphocytic leukemia. Nat Genet. 2016;48:253\u201364.","journal-title":"Nat Genet"},{"key":"2906_CR34","doi-asserted-by":"publisher","first-page":"2935","DOI":"10.1182\/blood.2020008311","volume":"137","author":"F Nadeu","year":"2021","unstructured":"Nadeu F, Royo R, Clot G, Duran-Ferrer M, Navarro A, Mart\u00edn S, et al. IGLV3-21R110 identifies an aggressive biological subtype of chronic lymphocytic leukemia with intermediate epigenetics. Blood. 2021;137:2935\u201346.","journal-title":"Blood"},{"key":"2906_CR35","doi-asserted-by":"publisher","first-page":"2474","DOI":"10.1182\/bloodadvances.2019000237","volume":"3","author":"TK Wojdacz","year":"2019","unstructured":"Wojdacz TK, Amarasinghe HE, Kadalayil L, Beattie A, Forster J, Blakemore SJ, et al. Clinical significance of DNA methylation in chronic lymphocytic leukemia patients: results from 3 UK clinical trials. Blood Adv. 2019;3:2474\u201381.","journal-title":"Blood Adv"},{"key":"2906_CR36","doi-asserted-by":"publisher","first-page":"2072","DOI":"10.1111\/bjh.19765","volume":"205","author":"L Carr","year":"2024","unstructured":"Carr L, Norris K, Parker H, Nilsson-Takeuchi A, Bryant D, Amarasinghe H, et al. Telomere length and DNA methylation epitype both provide independent prognostic information in CLL patients; data from the UK CLL4, ARCTIC and ADMIRE clinical trials. Br J Haematol. 2024;205:2072\u20136.","journal-title":"Br J Haematol"},{"key":"2906_CR37","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/S0140-6736(07)61125-8","volume":"370","author":"D Catovsky","year":"2007","unstructured":"Catovsky D, Richards S, Matutes E, Oscier D, Dyer M, Bezares RF, et al. Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial. Lancet. 2007;370:230\u20139.","journal-title":"Lancet"},{"key":"2906_CR38","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.1038\/leu.2017.65","volume":"31","author":"T Munir","year":"2017","unstructured":"Munir T, Howard DR, McParland L, Pocock C, Rawstron AC, Hockaday A, et al. Results of the randomized phase IIB ADMIRE trial of FCR with or without mitoxantrone in previously untreated CLL. Leukemia. 2017;31:2085\u201393.","journal-title":"Leukemia"},{"key":"2906_CR39","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.1038\/leu.2017.96","volume":"31","author":"DR Howard","year":"2017","unstructured":"Howard DR, Munir T, McParland L, Rawstron AC, Milligan D, Schuh A, et al. Results of the randomized phase IIB ARCTIC trial of low-dose rituximab in previously untreated CLL. Leukemia. 2017;31:2416\u201325.","journal-title":"Leukemia"},{"key":"2906_CR40","doi-asserted-by":"publisher","first-page":"1760","DOI":"10.1038\/s41375-020-0723-2","volume":"34","author":"SJ Blakemore","year":"2020","unstructured":"Blakemore SJ, Clifford R, Parker H, Antoniou P, Stec-Dziedzic E, Larrayoz M, et al. Clinical significance of TP53, BIRC3, ATM and MAPK-ERK genes in chronic lymphocytic leukaemia: data from the randomised UK LRF CLL4 trial. Leukemia. 2020;34:1760\u201374.","journal-title":"Leukemia"},{"key":"2906_CR41","doi-asserted-by":"publisher","first-page":"1942","DOI":"10.1182\/blood.V124.21.1942.1942","volume":"124","author":"RM Clifford","year":"2014","unstructured":"Clifford RM, Robbe P, Weller S, Timbs AT, Titsias M, Burns A, et al. Towards response prediction using integrated genomics in chronic lymphocytic leukaemia: results on 250 first-line FCR treated patients from UK clinical trials. Blood. 2014;124:1942.","journal-title":"Blood"},{"key":"2906_CR42","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1038\/leu.2010.288","volume":"25","author":"H Parker","year":"2011","unstructured":"Parker H, Rose-Zerilli MJ, Parker A, Chaplin T, Wade R, Gardiner A, et al. 13q deletion anatomy and disease progression in patients with chronic lymphocytic leukemia. Leukemia. 2011;25:489\u201397.","journal-title":"Leukemia"},{"key":"2906_CR43","doi-asserted-by":"publisher","first-page":"2179","DOI":"10.1038\/leu.2016.134","volume":"30","author":"H Parker","year":"2016","unstructured":"Parker H, Rose-Zerilli MJ, Larrayoz M, Clifford R, Edelmann J, Blakemore S, et al. Genomic disruption of the histone methyltransferase SETD2 in chronic lymphocytic leukaemia. Leukemia. 2016;30:2179\u201386.","journal-title":"Leukemia"},{"key":"2906_CR44","unstructured":"Hovestadt VZM. Conumee: enhanced copy-number variation analysis using Illumina DNA methylation arrays. R package version 1.9.0, http:\/\/bioconductor.org\/packages\/conumee\/."},{"key":"2906_CR45","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1007\/978-1-4939-8876-1_23","volume":"1881","author":"H Parker","year":"2019","unstructured":"Parker H, Carr L, Syeda S, Bryant D, Strefford JC. Characterization of somatically-acquired copy number alterations in chronic lymphocytic leukaemia using shallow whole genome sequencing. Methods Mol Biol. 2019;1881:327\u201353.","journal-title":"Methods Mol Biol"},{"key":"2906_CR46","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1002\/gcc.22350","volume":"55","author":"J Schoumans","year":"2016","unstructured":"Schoumans J, Suela J, Hastings R, Muehlematter D, Rack K, van den Berg E, et al. Guidelines for genomic array analysis in acquired haematological neoplastic disorders. Genes Chromosomes Cancer. 2016;55:480\u201391.","journal-title":"Genes Chromosomes Cancer"},{"key":"2906_CR47","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1038\/leu.2014.252","volume":"29","author":"AC Queir\u00f3s","year":"2015","unstructured":"Queir\u00f3s AC, Villamor N, Clot G, Martinez-Trillos A, Kulis M, Navarro A, et al. A B-cell epigenetic signature defines three biologic subgroups of chronic lymphocytic leukemia with clinical impact. Leukemia. 2015;29:598\u2013605.","journal-title":"Leukemia"},{"key":"2906_CR48","doi-asserted-by":"publisher","first-page":"5448","DOI":"10.1200\/JCO.2007.11.2649","volume":"25","author":"B Austen","year":"2007","unstructured":"Austen B, Skowronska A, Baker C, Powell JE, Gardiner A, Oscier D, et al. Mutation status of the residual ATM allele is an important determinant of the cellular response to chemotherapy and survival in patients with chronic lymphocytic leukemia containing an 11q deletion. J Clin Oncol. 2007;25:5448\u201357.","journal-title":"J Clin Oncol"},{"key":"2906_CR49","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1038\/leu.2011.281","volume":"26","author":"B Britt-Compton","year":"2012","unstructured":"Britt-Compton B, Lin T T, Ahmed G, Weston V, Jones RE, Fegan C, et al. Extreme telomere erosion in ATM-mutated and 11q-deleted CLL patients is independent of disease stage. Leukemia. 2012;26:826\u201330.","journal-title":"Leukemia"},{"key":"2906_CR50","doi-asserted-by":"publisher","first-page":"910","DOI":"10.4161\/epi.28603","volume":"9","author":"S Deneberg","year":"2014","unstructured":"Deneberg S, Kanduri M, Ali D, Bengtzen S, Karimi M, Qu Y, et al. microRNA-34b\/c on chromosome 11q23 is aberrantly methylated in chronic lymphocytic leukemia. Epigenetics. 2014;9:910\u20137.","journal-title":"Epigenetics"},{"key":"2906_CR51","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1158\/1078-0432.CCR-09-2534","volume":"16","author":"P Ouillette","year":"2010","unstructured":"Ouillette P, Fossum S, Parkin B, Ding L, Bockenstedt P, Al-Zoubi A, et al. Aggressive chronic lymphocytic leukemia with elevated genomic complexity is associated with multiple gene defects in the response to DNA double-strand breaks. Clin Cancer Res. 2010;16:835\u201347.","journal-title":"Clin Cancer Res"},{"key":"2906_CR52","doi-asserted-by":"publisher","first-page":"736","DOI":"10.3324\/haematol.2013.098574","volume":"99","author":"MJ Rose-Zerilli","year":"2014","unstructured":"Rose-Zerilli MJ, Forster J, Parker H, Parker A, Rodr\u00edguez AE, Chaplin T, et al. ATM mutation rather than BIRC3 deletion and\/or mutation predicts reduced survival in 11q-deleted chronic lymphocytic leukemia: data from the UK LRF CLL4 trial. Haematologica. 2014;99:736\u201342.","journal-title":"Haematologica"},{"key":"2906_CR53","doi-asserted-by":"publisher","first-page":"2854","DOI":"10.1182\/blood-2011-12-395673","volume":"119","author":"D Rossi","year":"2012","unstructured":"Rossi D, Fangazio M, Rasi S, Vaisitti T, Monti S, Cresta S, et al. Disruption of BIRC3 associates with fludarabine chemorefractoriness in TP53 wild-type chronic lymphocytic leukemia. Blood. 2012;119:2854\u201362.","journal-title":"Blood"},{"key":"2906_CR54","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1007\/s12185-017-2240-2","volume":"106","author":"S Yi","year":"2017","unstructured":"Yi S, Li H, Li Z, Xiong W, Liu H, Liu W, et al. The prognostic significance of 13q deletions of different sizes in patients with B-cell chronic lymphoproliferative disorders: a retrospective study. Int J Hematol. 2017;106:418\u201325.","journal-title":"Int J Hematol"},{"key":"2906_CR55","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1038\/s41586-018-0291-z","volume":"559","author":"M Zimmermann","year":"2018","unstructured":"Zimmermann M, Murina O, Reijns MAM, Agathanggelou A, Challis R, Tarnauskait\u0117 \u017d, et al. CRISPR screens identify genomic ribonucleotides as a source of PARP-trapping lesions. Nature. 2018;559:285\u20139.","journal-title":"Nature"},{"key":"2906_CR56","doi-asserted-by":"publisher","first-page":"8317","DOI":"10.1007\/s13277-015-3556-2","volume":"36","author":"P Dos Santos","year":"2015","unstructured":"Dos Santos P, Panero J, Palau Nagore V, Stanganelli C, Bezares RF, Slavutsky I. Telomere shortening associated with increased genomic complexity in chronic lymphocytic leukemia. Tumour Biol. 2015;36:8317\u201324.","journal-title":"Tumour Biol"},{"key":"2906_CR57","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1038\/sj.leu.2404417","volume":"21","author":"PG Longo","year":"2007","unstructured":"Longo PG, Laurenti L, Gobessi S, Petlickovski A, Pelosi M, Chiusolo P, et al. The Akt signaling pathway determines the different proliferative capacity of chronic lymphocytic leukemia B-cells from patients with progressive and stable disease. Leukemia. 2007;21:110\u201320.","journal-title":"Leukemia"},{"key":"2906_CR58","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-05174-7","volume":"7","author":"EE Huang","year":"2017","unstructured":"Huang EE, Tedone E, O\u2019Hara R, Cornelius C, Lai TP, Ludlow A, et al. The maintenance of telomere length in CD28+ T cells during T lymphocyte stimulation. Sci Rep. 2017;7:6785.","journal-title":"Sci Rep"},{"key":"2906_CR59","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1038\/nri890","volume":"2","author":"RJ Hodes","year":"2002","unstructured":"Hodes RJ, Hathcock KS, Weng NP. Telomeres in T and B cells. Nat Rev Immunol. 2002;2:699\u2013706.","journal-title":"Nat Rev Immunol"},{"key":"2906_CR60","doi-asserted-by":"publisher","DOI":"10.1016\/j.htct.2025.103822","volume":"47","author":"CS Chiattone","year":"2025","unstructured":"Chiattone CS, Marques FM, Buccheri V, Yamamoto M, Fortier SC, Ikoma-Colturato MRV, et al. Diagnosis and treatment of chronic lymphocytic leukemia: 2025 recommendations of the Brazilian Group of Chronic Lymphocytic Leukemia of the Brazilian Association of Hematology and Hemotherapy (ABHH). Hematol Transfus Cell Ther. 2025;47:103822.","journal-title":"Hematol Transfus Cell Ther"},{"key":"2906_CR61","doi-asserted-by":"publisher","first-page":"5446","DOI":"10.1182\/blood-2007-06-093906","volume":"111","author":"M Hallek","year":"2008","unstructured":"Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, D\u00f6hner H, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood. 2008;111:5446\u201356.","journal-title":"Blood"},{"key":"2906_CR62","first-page":"22","volume":"32","author":"B Eichhorst","year":"2021","unstructured":"Eichhorst B, Robak T, Montserrat E, Ghia P, Niemann CU, Kater AP, et al. Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. EMSO Ann Oncol. 2021;32:22\u201333.","journal-title":"EMSO Ann Oncol"},{"key":"2906_CR63","doi-asserted-by":"publisher","first-page":"2296","DOI":"10.1111\/bjh.70100","volume":"207","author":"R Walewska","year":"2025","unstructured":"Walewska R, Eyre TA, Bloor A, Follows G, Iyengar S, Johnston R, et al. 2025 British Society for Haematology Guideline for the treatment of chronic lymphocytic leukaemia. Br J Haematol. 2025;207:2296\u2013313.","journal-title":"Br J Haematol"},{"key":"2906_CR64","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1080\/10428194.2024.2449214","volume":"66","author":"S McKeague","year":"2025","unstructured":"McKeague S, Tam C. Prognostic factors in chronic lymphocytic leukaemia - the old, the new and the future. Leuk Lymphoma. 2025;66:847\u201357.","journal-title":"Leuk Lymphoma"},{"key":"2906_CR65","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1038\/ng.2584","volume":"45","author":"AJ Ramsay","year":"2013","unstructured":"Ramsay AJ, Quesada V, Foronda M, Conde L, Mart\u00ednez-Trillos A, Villamor N, et al. POT1 mutations cause telomere dysfunction in chronic lymphocytic leukemia. Nat Genet. 2013;45:526\u201330.","journal-title":"Nat Genet"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-02906-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-02906-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-02906-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T11:03:21Z","timestamp":1775559801000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-02906-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,11]]},"references-count":65,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["2906"],"URL":"https:\/\/doi.org\/10.1038\/s41375-026-02906-5","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,11]]},"assertion":[{"value":"13 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"DMB, KN and CP are founding shareholders of TeloNostiX Ltd.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}